Leronlimab and TNBC etc Naming the Barriers bet
Post# of 153887
(Total Views: 677)
Posted On: 11/16/2022 11:09:55 AM
Leronlimab and TNBC etc
Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment
Belonging to a different pharmacological family, Leronlimab is a humanized igG4k monoclonal antibody also able to bind CCR5. Adams et al. [69] recently reported some clinical trials testing Leronlimab in metastatic TNBC patients. The phase 1b/2 dose escalation (NCT03838367), Compassionate Use (NCT04313075) and the Basket Study (NCT04504942) were pooled in order to evaluate the drug’s safety and efficacy at 12 months. After the analysis of 28 metastatic TNBC patients, the authors showed that Leronlimab has significant antitumor activity. The clinical trials suggest that metastatic TNBC patients dosed with Leronlimab have a real clinical benefit with improved 1-year progression-free and overall survival and few treatment-emergent adverse events. Finally, after exploring the effect of Leronlimab on circulating tumor-associated cells (TACs) from peripheral blood, the authors revealed that Leronlimab resulted in a drop in circulating TACs in the majority of patients correlating with early therapy response.
https://www.mdpi.com/1422-0067/23/22/14159/htm
Credit Bluemoon @ Investor Village
Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment
Belonging to a different pharmacological family, Leronlimab is a humanized igG4k monoclonal antibody also able to bind CCR5. Adams et al. [69] recently reported some clinical trials testing Leronlimab in metastatic TNBC patients. The phase 1b/2 dose escalation (NCT03838367), Compassionate Use (NCT04313075) and the Basket Study (NCT04504942) were pooled in order to evaluate the drug’s safety and efficacy at 12 months. After the analysis of 28 metastatic TNBC patients, the authors showed that Leronlimab has significant antitumor activity. The clinical trials suggest that metastatic TNBC patients dosed with Leronlimab have a real clinical benefit with improved 1-year progression-free and overall survival and few treatment-emergent adverse events. Finally, after exploring the effect of Leronlimab on circulating tumor-associated cells (TACs) from peripheral blood, the authors revealed that Leronlimab resulted in a drop in circulating TACs in the majority of patients correlating with early therapy response.
https://www.mdpi.com/1422-0067/23/22/14159/htm
Credit Bluemoon @ Investor Village
(2)
(0)